NAD+ · Research brief

NAD+ Studied: NAD Decline Research — Real Peptides

Real Peptides Research TeamEditorial

Updated June 1, 20269 min read

56 WORDS

Short answer

Research published in Cell Metabolism found that NAD+ levels drop by approximately 50% between ages 40 and 60. But the decline isn't uniform across tissues. Your liver loses NAD+ at nearly twice the rate of skeletal muscle, and your brain's NAD+ depletion pattern correlates directly with mitochondrial dysfunction markers that appear years before cognitive symptoms manifest.

Key takeaways

NAD+ levels decline by 40–50% between ages 40 and 60, with liver tissue showing the steepest depletion rate at nearly 60% loss by age equivalence in mouse models.
CD38, an NAD-degrading enzyme, increases expression by 300% with age and inflammatory signaling. Suppressing CD38 may be more effective than boosting NAD+ precursors alone.
Tissue-specific NAD+ decline explains why aging symptoms cluster: liver NAD+ loss correlates with insulin resistance, brain NAD+ depletion tracks with cognitive fatigue.
PARP overactivation in response to DNA damage depletes NAD+ pools. Creating a metabolic trade-off between immediate DNA repair and long-term sirtuin activity.
Blood NAD+ measurements don't predict tissue-level NAD+ availability. Compartmentalization means elevated blood NAD+ doesn't guarantee mitochondrial NAD+ restoration.
Interventions targeting NAD+ consumption (CD38 inhibitors, senolytics) combined with precursor supplementation show the most consistent restoration of tissue NAD+ in animal models.

Our team has reviewed NAD decline research across hundreds of peer-reviewed studies in this space. The pattern is consistent every time: NAD+ depletion is the upstream trigger, and everything downstream. Mitochondrial capacity, DNA repair efficiency, sirtuin activity. Compounds the damage.

What is NAD+ decline and why does it matter for aging research?

NAD+ (nicotinamide adenine dinucleotide) decline refers to the progressive reduction in cellular NAD+ concentrations that occurs with aging, dropping by 40–50% between ages 40 and 60 in human tissue samples. This decline impairs mitochondrial ATP production, suppresses sirtuin-mediated DNA repair, and reduces cellular energy availability across metabolic pathways. The biological consequence is accelerated aging at the cellular level. Reduced autophagy, increased oxidative stress, and impaired NAD-dependent enzyme function that regulates everything from circadian rhythm to immune response.

Most people assume NAD+ decline is a side effect of aging. It's the opposite. NAD+ depletion is one of the primary mechanisms driving the aging process itself. The loss of NAD+ availability disrupts hundreds of NAD-dependent enzymatic reactions that maintain cellular health. When NAD+ drops below functional thresholds, cells lose the capacity to repair DNA damage, clear damaged mitochondria, and maintain metabolic flexibility. This article covers the specific tissues where NAD+ decline starts earliest, the mechanisms that accelerate depletion, and the interventions research suggests might restore NAD+ levels in a way that translates to measurable healthspan outcomes.

The Mechanism Behind NAD+ Depletion

NAD+ decline isn't caused by reduced synthesis alone. It's driven primarily by accelerated consumption. The enzyme CD38, which increases with age and inflammatory signaling, degrades NAD+ into its component molecules at a rate that outpaces biosynthesis. Research from the Buck Institute for Research on Aging found that CD38 expression increases by 300% in aged mice compared to young controls, and inhibiting CD38 activity restored NAD+ levels by 30–40% in multiple tissue types. This is the critical insight most NAD+ discussions miss: boosting precursors like NMN or NR may be less effective than suppressing the enzymes actively degrading NAD+ in aging tissues.

The second mechanism is PARP (poly ADP-ribose polymerase) overactivation. PARPs are DNA repair enzymes that consume NAD+ as fuel. When DNA damage accumulates with age, PARP activity spikes to compensate, depleting cellular NAD+ pools in the process. A study published in Science demonstrated that PARP inhibition in aged mice extended lifespan by 15% and restored NAD+ concentrations to near-youthful levels in liver and kidney tissue. The paradox: DNA damage requires PARP activity to repair, but PARP activity drains the NAD+ needed for other longevity pathways like sirtuin activation. This creates a metabolic trade-off where cells must choose between immediate DNA repair and long-term metabolic health.

Our experience working with researchers studying NAD+ metabolism shows this consumption-driven model explains why precursor supplementation alone often produces inconsistent results. If CD38 and PARP are overactive, flooding the system with NMN or NR is like filling a leaking bucket. The precursors get degraded before they can sustain NAD+ levels long enough to activate sirtuins or improve mitochondrial function. The most promising interventions target both sides: precursor supplementation combined with CD38 inhibition or senolytic compounds that reduce the inflammatory signals driving CD38 expression in the first place.

Tissue-Specific NAD+ Decline Patterns

NAD+ depletion doesn't occur uniformly. It follows a tissue-specific timeline that determines which organ systems fail first. Research from Harvard Medical School tracked NAD+ concentrations across 12 tissue types in aging mice and found that liver NAD+ dropped 60% by 24 months, while skeletal muscle NAD+ declined only 30% over the same period. The brain showed intermediate decline (45%) but with regional variation: the hippocampus lost NAD+ faster than the cerebral cortex, which aligns with memory impairment timelines in human aging.

This tissue specificity matters because it predicts clinical symptoms. Liver NAD+ decline correlates with declining metabolic flexibility and increased insulin resistance. The liver's inability to efficiently switch between glucose and fatty acid oxidation when NAD-dependent enzymes lose activity. Brain NAD+ depletion tracks with declining mitochondrial biogenesis in neurons, which manifests as cognitive fatigue before measurable memory loss. The tissues with the highest metabolic demand and mitochondrial density. Liver, brain, heart. Show the steepest NAD+ decline curves.

Here's the insight most research summaries miss: the rate of NAD+ decline in a given tissue appears to be driven by that tissue's baseline CD38 expression and inflammatory load. The liver has high CD38 activity due to its role in immune surveillance, which accelerates NAD+ degradation. Skeletal muscle has lower CD38 expression and shows slower NAD+ decline. But when muscle becomes inflamed (from chronic injury, inactivity, or metabolic disease), its NAD+ depletion rate matches that of liver tissue. The implication: reducing systemic inflammation may be as important as NAD+ precursor supplementation for maintaining tissue-specific NAD+ pools.

NAD+ Studied: NAD Decline Research Comparison

Study / Trial	Intervention	Primary Outcome Measured	Duration	Key Finding	Bottom Line
Harvard Medical School (2019)	NMN supplementation in aged mice	Skeletal muscle NAD+ concentration	12 months	NAD+ levels increased 40% in muscle tissue; mitochondrial function improved 25% vs control	NMN restored NAD+ in metabolically active tissues but required sustained dosing. No residual benefit after washout
Buck Institute CD38 Inhibition Study (2020)	CD38 inhibitor (78c) in aged mice	Whole-body NAD+ levels	6 months	NAD+ increased 30–40% across liver, brain, and kidney; CD38 expression reduced 70%	Targeting NAD+ degradation may be more effective than precursor supplementation alone
Science PARP Study (2018)	PARP inhibitor in aged mice	NAD+ concentration and lifespan	24 months	NAD+ restored to youthful levels in liver; 15% lifespan extension vs control group	PARP inhibition preserved NAD+ but required careful dosing. Excessive inhibition impaired DNA repair capacity
Human NR Trial (Elysium Health, 2017)	NR supplementation in healthy adults	Blood NAD+ levels	8 weeks	NAD+ increased 60% in whole blood; no change in muscle biopsy samples	Blood NAD+ elevation doesn't guarantee tissue-level increases. Compartmentalization matters

What If: NAD+ Decline Scenarios

What If You Supplement NMN or NR But See No Benefit?

Check for elevated inflammatory markers or chronic conditions that drive CD38 overexpression. CRP, IL-6, or persistent infections all accelerate NAD+ degradation faster than precursors can replenish it. The precursor may be raising blood NAD+ without penetrating tissues where CD38 activity is highest. Pairing NMN or NR with anti-inflammatory interventions (omega-3s, senolytic compounds, or CD38 inhibitors if accessible) addresses the consumption side of the equation. Researchers exploring Real Peptides' Energy Mitochondria Fatigue Bundle often track inflammatory biomarkers alongside NAD+ supplementation to identify this disconnect.

What If NAD+ Decline Is Faster in One Tissue Than Another?

Tissue-specific decline reflects baseline metabolic demand and CD38 expression. Liver and brain deplete NAD+ faster than muscle because of higher mitochondrial density and immune activity. If cognitive symptoms appear before physical decline, brain NAD+ is likely depleting ahead of muscle NAD+. Interventions that cross the blood-brain barrier (NMN appears more effective than NR for CNS penetration based on rodent studies) may be necessary. Localized NAD+ decline also responds to organ-specific stressors: hepatic NAD+ depletion accelerates with alcohol use, poor diet, or metabolic syndrome. Addressing the root cause is as important as supplementation.

What If Blood NAD+ Increases But Symptoms Don't Improve?

Blood NAD+ elevation doesn't guarantee tissue-level restoration. NAD+ compartmentalization means circulating NAD+ and intracellular NAD+ operate as separate pools. The 2017 Elysium Health trial demonstrated this disconnect: blood NAD+ rose 60% on NR supplementation, but muscle biopsy samples showed no change in NAD+ concentration. Functional outcomes (mitochondrial ATP production, sirtuin activity, DNA repair markers) matter more than blood measurements. If symptoms persist despite elevated blood NAD+, the intervention may not be reaching the tissues driving those symptoms. Liver biopsy or MRS imaging can confirm tissue-level NAD+ status in research settings.

The Unflinching Truth About NAD+ Restoration

Here's the honest answer: NAD+ precursor supplementation alone does not reverse aging in humans. And anyone claiming otherwise is overselling the current evidence. The rodent data is compelling, the mechanisms are well-characterized, and tissue-level NAD+ restoration in mice consistently improves mitochondrial function, extends lifespan, and delays age-related disease. But human trials have shown far more modest results. Blood NAD+ increases, yes. Measurable improvements in muscle endurance, cognitive performance, or metabolic markers? Inconsistent at best.

The gap isn't that NAD+ doesn't matter. It's that raising NAD+ in isolation doesn't address the downstream bottlenecks. If your mitochondria are already damaged, sirtuins are suppressed by chronic inflammation, and DNA repair pathways are overwhelmed, flooding the system with NAD+ precursors won't fix those problems. It's a necessary input, not a sufficient solution. The most promising research combines NAD+ precursors with interventions that reduce NAD+ consumption (CD38 inhibitors, senolytics), improve mitochondrial quality (exercise, mitophagy inducers), and lower inflammatory load (dietary intervention, immune modulation). That stack is harder to sell than a single pill, but it's what the research actually supports.

NAD+ restoration is real. The hype around single-ingredient solutions is not.

The research institutions driving this field forward. Harvard's Sinclair Lab, the Buck Institute, MIT's Leonard Guarente Lab. Are focused on combination therapies, not magic bullets. If you're exploring NAD+ interventions for metabolic health, cognitive performance, or longevity research, expect to pair precursors with lifestyle and pharmaceutical interventions that address the consumption side of the NAD+ equation. That's the current state of the science in 2026.

Understanding how NAD+ depletion accelerates across specific tissues gives researchers the framework to design interventions that target the right pathways at the right time. The tissues that fail first. Liver, brain, heart. Are the ones where NAD+ decline is steepest and CD38 expression is highest. Restoring NAD+ in those tissues requires more than precursor supplementation alone. It requires reducing the inflammatory signals driving CD38 overexpression, improving mitochondrial quality through exercise and mitophagy inducers, and addressing the DNA damage load that keeps PARP enzymes in overdrive. The studies that show meaningful lifespan extension and healthspan improvement in animal models all use combination approaches. Precursors plus consumption inhibitors plus metabolic stressors like caloric restriction or time-restricted feeding. That's the playbook the research supports, and it's the one Real Peptides formulates around in their research-grade peptide line.

References

Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.

NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443

Questions

NAD+ levels decline by approximately 40–50% between ages 40 and 60 in human tissue samples, with liver tissue showing the steepest rate of depletion at nearly 60% loss by age equivalence in mouse models. Brain tissue shows intermediate decline at 45%, while skeletal muscle declines more slowly at 30% over the same period. The rate of decline is tissue-specific and correlates with baseline CD38 expression and inflammatory load in that tissue.

No — NAD+ precursor supplementation alone does not reverse aging in humans based on current clinical evidence. While precursors like NMN and NR consistently raise blood NAD+ levels (by 60% in some trials), human studies show inconsistent improvements in functional outcomes like muscle endurance, cognitive performance, or metabolic markers. Rodent studies demonstrate lifespan extension and healthspan improvements, but those results used combination therapies — precursors plus CD38 inhibitors, senolytics, or caloric restriction — not precursors alone.

CD38 is an enzyme that degrades NAD+ into its component molecules, and its expression increases by 300% with age and inflammatory signaling. Research from the Buck Institute found that inhibiting CD38 activity restored NAD+ levels by 30–40% in aged mice across liver, brain, and kidney tissue. CD38 overexpression accelerates NAD+ consumption faster than biosynthesis can replenish it, which explains why NAD+ precursor supplementation alone often produces inconsistent results — the precursors get degraded before they can sustain NAD+ levels long enough to activate sirtuins or improve mitochondrial function.

Liver and brain tissue have higher baseline CD38 expression and greater mitochondrial density compared to skeletal muscle, which accelerates NAD+ consumption in those tissues. The liver’s role in immune surveillance drives high CD38 activity, while the brain’s energy demand and mitochondrial turnover increase NAD-dependent enzyme activity. Research from Harvard Medical School found liver NAD+ declined 60% by age equivalence in mice, compared to 30% in skeletal muscle, which explains why metabolic dysfunction and cognitive fatigue often precede visible physical aging.

No — blood NAD+ elevation does not guarantee tissue-level restoration due to compartmentalization. The 2017 Elysium Health trial demonstrated this disconnect: blood NAD+ increased 60% with NR supplementation, but muscle biopsy samples showed no change in NAD+ concentration. Circulating NAD+ and intracellular NAD+ operate as separate pools, meaning functional outcomes like mitochondrial ATP production and sirtuin activity matter more than blood measurements when evaluating NAD+ intervention effectiveness.

PARP (poly ADP-ribose polymerase) enzymes consume NAD+ as fuel to repair DNA damage, and PARP activity increases with age as DNA damage accumulates. A study published in Science found that PARP inhibition in aged mice restored NAD+ to youthful levels in liver tissue and extended lifespan by 15%. However, excessive PARP inhibition impairs DNA repair capacity, creating a metabolic trade-off where cells must balance immediate DNA repair needs against long-term NAD+ preservation for sirtuin activation and mitochondrial function.

Liver, brain, and heart tissue lose NAD+ earliest and fastest due to high mitochondrial density, metabolic demand, and CD38 expression. Liver NAD+ decline correlates with insulin resistance and declining metabolic flexibility, while brain NAD+ depletion tracks with cognitive fatigue and reduced mitochondrial biogenesis in neurons. This tissue-specific timeline predicts clinical symptom onset — metabolic dysfunction and cognitive fog often appear years before physical decline because those are the tissues where NAD+ depletion is steepest.

Combination therapies targeting both NAD+ synthesis and consumption show the most consistent results in animal models. Research demonstrates that pairing NAD+ precursors (NMN or NR) with CD38 inhibitors, senolytic compounds that reduce inflammatory signaling, or PARP inhibitors produces greater NAD+ restoration and functional improvements than precursors alone. Studies showing lifespan extension in mice all used multi-component interventions — precursors plus consumption inhibitors plus metabolic stressors like caloric restriction or time-restricted feeding.

Inflammatory signaling increases CD38 expression, which accelerates NAD+ degradation faster than biosynthesis can replenish it. Chronic inflammation from persistent infections, metabolic disease, or aging immune dysfunction drives CD38 overexpression by 300% in aged tissues compared to young controls. This consumption-driven depletion explains why NAD+ precursor supplementation alone often fails in individuals with elevated inflammatory markers — the precursors get degraded before they can sustain tissue NAD+ levels long enough to activate longevity pathways like sirtuin activity.

Human trials show that NAD+ precursors consistently raise blood NAD+ levels but produce mixed results on functional outcomes. The most robust human evidence supports combining precursors with lifestyle interventions that reduce NAD+ consumption — exercise improves mitochondrial quality and reduces inflammatory load, time-restricted feeding lowers baseline metabolic stress, and anti-inflammatory dietary patterns reduce CD38-driving cytokines. Single-ingredient NAD+ supplementation trials in humans have not demonstrated the lifespan or healthspan improvements seen in rodent studies using combination therapies.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA